The Neuroprotective Agent CNTF Decreases Neuronal Metabolites in the Rat Striatum: An in Vivo Multimodal Magnetic Resonance Imaging Study

Ciliary neurotrophic factor (CNTF) is neuroprotective against multiple pathologic conditions including metabolic impairment, but the mechanisms are still unclear. To delineate CNTF effects on brain energy homeostasis, we performed a multimodal imaging study, combining in vivo proton magnetic resonance spectroscopy, high-performance liquid chromatography analysis, and in situ glutamate imaging by chemical exchange saturation transfer. Unexpectedly, we found that CNTF expression through lentiviral gene transfer in the rat striatum significantly decreased the levels of neuronal metabolites (N-acetyl-aspartate, N-acetyl-aspartyl-glutamate, and glutamate). This preclinical study shows that CNTF remodels brain metabolism, and suggests that decreased levels of neuronal metabolites may occur in the absence of neuronal dysfunction.

[1]  N. Déglon,et al.  Neuroprotective Effect of a CNTF-Expressing Lentiviral Vector in the Quinolinic Acid Rat Model of Huntington's Disease , 2001, Neurobiology of Disease.

[2]  Ashley R. Jones,et al.  Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients , 2016, NeuroMolecular Medicine.

[3]  J. Bloch,et al.  Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. , 2000, Human gene therapy.

[4]  Philippe Hantraye,et al.  Reactive Astrocytes Overexpress TSPO and Are Detected by TSPO Positron Emission Tomography Imaging , 2012, The Journal of Neuroscience.

[5]  Philippe Hantraye,et al.  Ciliary Neurotrophic Factor Activates Astrocytes, Redistributes Their Glutamate Transporters GLAST and GLT-1 to Raft Microdomains, and Improves Glutamate Handling In Vivo , 2006, The Journal of Neuroscience.

[6]  M. Peschanski,et al.  Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease , 1997, Nature.

[7]  J. Moffett,et al.  N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.

[8]  Myriam Schluep,et al.  Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients , 1996, Nature Medicine.

[9]  M. Peschanski,et al.  Corticostriatopallidal Neuroprotection by Adenovirus-Mediated Ciliary Neurotrophic Factor Gene Transfer in a Rat Model of Progressive Striatal Degeneration , 2002, The Journal of Neuroscience.

[10]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[11]  John A. Detre,et al.  Magnetic Resonance Imaging of Glutamate , 2011, Nature Medicine.

[12]  P. Gubellini,et al.  Ciliary Neurotrophic Factor Protects Striatal Neurons against Excitotoxicity by Enhancing Glial Glutamate Uptake , 2010, PloS one.

[13]  Marc Dhenain,et al.  Activation of Astrocytes by CNTF Induces Metabolic Plasticity and Increases Resistance to Metabolic Insults , 2007, The Journal of Neuroscience.

[14]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[15]  J. Kordower,et al.  Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntington’s Disease , 1996, The Journal of Neuroscience.

[16]  B. Trapp,et al.  Postmortem Degradation of N-Acetyl Aspartate and N-Acetyl Aspartylglutamate: An HPLC Analysis of Different Rat CNS Regions , 2001, Neurochemical Research.

[17]  M. Febbraio,et al.  CNTF: a target therapeutic for obesity-related metabolic disease? , 2008, Journal of Molecular Medicine.

[18]  D. Emerich,et al.  Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa. , 2006, Current gene therapy.

[19]  J. Moffett,et al.  N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation , 2013, Front. Neuroenergetics.

[20]  Weng Tao,et al.  Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P Aebischer,et al.  Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. , 2004, Human gene therapy.

[22]  N. Déglon,et al.  Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. , 2002, Human gene therapy.